An early study reported that Metacept, a highly cytotoxic class I HDAC inhibitor (Shehu-Xhilaga et al., 2009), ameliorated Ang-II-induced aneurysm incidence without any beneficial effect on mortality rates (Vinh et al., 2008). Here, HDAC9 is linked to aneurysm.